UTHRUNITED THERAPEUTICS Corpvs its industry peers
A metric-by-metric comparison of UNITED THERAPEUTICS Corp against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UTHRThis | $21.4B#13 | 17.9x#2 | 3.3x#2 | 6.7x#5 | 10.6%#6 | 11.7%#10 | 46.9%#2 | 20.9%#6 | — | — | 25.3%#6 | — |
| VRTX | $130.0B#4 | 29.9x#6 | 6.4x#4 | 10.8x#8 | 8.9%#8 | 838.1%#3 | 34.8%#3 | 19.5%#7 | 25.0%#5 | — | 31.1%#5 | — |
| AMGN | $203.5B#2 | 23.4x#5 | 17.4x#9 | 5.5x#3 | 10.0%#7 | 88.5%#7 | 24.7%#8 | 66.0%#2 | 15.1%#7 | — | 41.3%#2 | 2.5%#1 |
| GILD | $183.2B#3 | — | 15.5x#7 | 6.2x#4 | 2.4%#9 | 1672.9%#2 | 34.0%#4 | 71.9%#1 | 26.7%#4 | — | 36.2%#3 | 2.2%#2 |
| REGN | — | 19.2x#3 | — | — | 1.0%#11 | 2.1%#11 | 24.9%#7 | 14.2%#8 | 9.4%#9 | — | 34.7%#4 | — |
| ARGX | $61.0B#5 | — | — | 1715.5x#12 | 254.4%#1 | 55.1%#8 | 2965.7%#1 | — | — | — | — | — |
| ALNY | $32.0B#10 | 41.7x#7 | 23.7x#10 | 8.6x#7 | 65.2%#2 | 212.8%#4 | 13.5%#10 | 23.2%#4 | 150.5%#1 | — | — | — |
| NTRA | $49.8B#7 | — | 27.3x#11 | 21.6x#9 | 35.9%#4 | -9.3%#12 | -13.4%#12 | -11.4%#11 | -18.0%#10 | — | 97.4%#1 | — |
| RVMD | $42.0B#8 | — | 16.1x#8 | — | — | -88.5%#14 | — | -43.4%#13 | — | — | — | — |
| BIIB | $31.9B#11 | 23.2x#4 | 2.2x#1 | 3.2x#1 | 2.2%#10 | -20.8%#13 | 28.7%#6 | 8.7%#9 | 13.0%#8 | 4#3 | — | — |
| ILMN | $34.6B#9 | 42.7x#8 | 12.2x#6 | 8.0x#6 | -0.7%#12 | 169.5%#5 | 18.6%#9 | 30.0%#3 | 22.0%#6 | 7#1 | — | — |
| MRNA | $58.1B#6 | — | 8.6x#5 | 29.9x#10 | -39.9%#13 | 20.8%#9 | -158.1%#13 | -41.7%#12 | -54.6%#11 | — | — | — |
| ONC | $514.8B#1 | 810.0x#9 | 99.5x#12 | 96.4x#11 | 40.2%#3 | 144.5%#6 | 8.4%#11 | 5.5%#10 | 29.9%#3 | 6#2 | 6.5%#7 | — |
| INCY | $24.9B#12 | 17.6x#1 | 4.4x#3 | 4.8x#2 | 21.2%#5 | 3846.9%#1 | 29.5%#5 | 22.9%#5 | 49.0%#2 | — | — | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice